Domača stranGIFOF • OTCMKTS
add
Grifols SA Preference Shares Class B
Prejšnji trg. dan.
7,42 $
Letni razpon
5,58 $ - 9,40 $
Tržna kapitalizacija
5,97 mrd. USD
Povprečni obseg
10,00
Razm. P/E
-
Dividendna donosnost
-
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
(EUR) | sep. 2024info | Sprememba L/L |
---|---|---|
Prihodek | 1,79 mrd. | 12,24 % |
Stroški poslovanja | 376,78 mio. | −3,08 % |
Čisti dohodek | 51,69 mio. | −13,19 % |
Čista dobičkovnost prihodkov | 2,88 | −22,79 % |
Earnings per share | — | — |
EBITDA | 468,09 mio. | 33,73 % |
Efektivna davčna stopnja | 31,35 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
(EUR) | sep. 2024info | Sprememba L/L |
---|---|---|
Denar. in kratkor. naložbe | 806,74 mio. | 66,60 % |
Skupna sredstva | 20,28 mrd. | −8,07 % |
Skupne obveznosti | 12,29 mrd. | −8,95 % |
Celoten lastniški kapital | 8,00 mrd. | — |
Shares outstanding | 679,63 mio. | — |
Razmerje P/B | 0,94 | — |
Donosnost sredstev | 4,22 % | — |
Donosnost kapitala | 4,78 % | — |
Denarni tok
Neto sprememba denarnih sredstev
(EUR) | sep. 2024info | Sprememba L/L |
---|---|---|
Čisti dohodek | 51,69 mio. | −13,19 % |
Denar iz dejavnosti | 299,61 mio. | 92,51 % |
Denar iz naložb | −196,40 mio. | −59,83 % |
Denar iz financiranja | −1,56 mrd. | −1.860,81 % |
Neto sprememba denarnih sredstev | −1,47 mrd. | −3.652,69 % |
Prost denarni tok | 243,60 mio. | 627,76 % |
Vizitka
Grifols, S.A. is a global healthcare company and manufacturer of plasma-derived medicines founded in Barcelona, Spain, in 1909. With a workforce of over 23,000employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products, a field in which it is the European leader and third largest worldwide, and other biopharmaceutical solutions, the company is also a leader in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Its portfolio of solutions is designed to enhance safety from donation to transfusion. Grifols also provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. Additionally, the company supply tools, information and services that enable hospitals, pharmacies and healthcare professionals to deliver expert medical care. Wikipedia
Generalni direktor
Datum ustanovitve
18. nov. 1940
Spletno mesto
Zaposleni
23.000